Li Dean Y, Executive VP and President of MRL, sold Merck & Co. ($MRK) shares on the open market twice in the last year, totaling nearly $3 million. The most recent sale occurred on February 10, 2026. These sales rank 2,729th among 11,678 insiders in our database, where the average is $8.6 million across 6.4 transactions per person. Li Dean Y made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Class A Common Stock | 3268 | $0.00 | 3,224,206.0000 | 514,895,802 | 0.10% | 0.00% |
| Feb. 10, 2026 | Merck & Co., Inc. | $MRK | Li Dean Y | Executive VP & President, MRL | S | Common Stock | 10235 | $117.52 | 92,035.0500 | 2,514,000,000 | 10.01% | 0.00% |
| Feb. 4, 2026 | Merck & Co., Inc. | $MRK | Li Dean Y | Executive VP & President, MRL | M | Common Stock | 15087 | $56.04 | 117,357.0500 | 2,514,000,000 | 14.75% | 0.00% |
| Feb. 4, 2026 | Merck & Co., Inc. | $MRK | Li Dean Y | Executive VP & President, MRL | M | Stock Option (Right to Buy) | 15087 | $0.00 | 0.0000 | 2,514,000,000 | 100.00% | 0.00% |
| Feb. 4, 2026 | Merck & Co., Inc. | $MRK | Li Dean Y | Executive VP & President, MRL | S | Common Stock | 15087 | $118.77 | 102,270.0500 | 2,514,000,000 | 12.86% | 0.00% |
| Jan. 26, 2026 | Merck & Co., Inc. | $MRK | Li Dean Y | Executive VP & President, MRL | A | Common Stock | 20469 | $107.40 | 102,270.0500 | 2,514,000,000 | 25.02% | 0.00% |
| Jan. 2, 2026 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Class A Common Stock | 2381 | $0.00 | 3,220,938.0000 | 514,895,802 | 0.07% | 0.00% |
| Oct. 1, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Class A Common Stock | 1961 | $0.00 | 3,218,557.0000 | 395,072,094 | 0.06% | 0.00% |
| July 1, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Class A Common Stock | 1949 | $0.00 | 3,216,596.0000 | 395,072,094 | 0.06% | 0.00% |
| June 18, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Class A Common Stock | 22016 | $0.00 | 3,214,647.0000 | 395,072,094 | 0.69% | 0.01% |
| June 18, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Stock Option (Right to Buy) | 44031 | $0.00 | 44,031.0000 | 395,072,094 | 9999.99% | 0.01% |
| April 29, 2025 | Merck & Co., Inc. | $MRK | Li Dean Y | Executive VP & President, MRL | A | Restricted Stock Unit | 14166 | $0.00 | 14,166.0000 | 2,541,000,000 | 9999.99% | 0.00% |
| April 29, 2025 | Merck & Co., Inc. | $MRK | Li Dean Y | Executive VP & President, MRL | A | Stock Option (Right to Buy) | 64481 | $0.00 | 64,481.0000 | 2,541,000,000 | 9999.99% | 0.00% |
| April 1, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Class A Common Stock | 2268 | $0.00 | 3,192,462.0000 | 395,072,094 | 0.07% | 0.00% |
| Jan. 27, 2025 | Merck & Co., Inc. | $MRK | Li Dean Y | Executive VP & President, MRL | A | Common Stock | 32621 | $97.94 | 79,592.1500 | 2,541,000,000 | 69.45% | 0.00% |
| Jan. 2, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Class A Common Stock | 1647 | $0.00 | 3,190,194.0000 | 0 | 0.05% | 0.00% |
| Oct. 1, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Class A Common Stock | 1925 | $0.00 | 3,188,547.0000 | 0 | 0.06% | 0.00% |
| July 1, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Class A Common Stock | 1592 | $0.00 | 3,186,622.0000 | 0 | 0.05% | 0.00% |
| June 3, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Stock Option (Right to Buy) | 26193 | $0.00 | 26,193.0000 | 0 | 9999.99% | 0.00% |
| June 3, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Class A Common Stock | 13097 | $0.00 | 3,185,030.0000 | 0 | 0.41% | 0.00% |
| April 30, 2024 | Merck & Co., Inc. | $MRK | Li Dean Y | Executive VP & President, MRL | A | Stock Option (Right to Buy) | 65625 | $0.00 | 65,625.0000 | 2,547,000,000 | 9999.99% | 0.00% |
| April 1, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Class A Common Stock | 1267 | $0.00 | 3,171,933.0000 | 0 | 0.04% | 0.00% |
| Feb. 9, 2024 | Merck & Co., Inc. | $MRK | Li Dean Y | Executive VP & President, MRL | M | Common Stock | 14702 | $62.07 | 60,944.3700 | 2,547,000,000 | 31.79% | 0.00% |
| Feb. 9, 2024 | Merck & Co., Inc. | $MRK | Li Dean Y | Executive VP & President, MRL | M | Stock Option (Right to Buy) | 14702 | $0.00 | 0.0000 | 2,547,000,000 | 100.00% | 0.00% |
| Feb. 9, 2024 | Merck & Co., Inc. | $MRK | Li Dean Y | Executive VP & President, MRL | S | Common Stock | 14702 | $125.50 | 46,242.3700 | 2,547,000,000 | 24.12% | 0.00% |
| Jan. 22, 2024 | Merck & Co., Inc. | $MRK | Li Dean Y | Executive VP & President, MRL | A | Common Stock | 25760 | $119.43 | 46,242.3700 | 2,547,000,000 | 125.77% | 0.00% |
| Jan. 9, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | S | Class A Common Stock | 962 | $14.03 | 3,170,666.0000 | 0 | 0.03% | 0.00% |
| Jan. 9, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | S | Class A Common Stock | 28038 | $13.65 | 3,171,628.0000 | 0 | 0.88% | 0.00% |
| Jan. 2, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Class A Common Stock | 1203 | $0.00 | 3,199,666.0000 | 0 | 0.04% | 0.00% |
| Oct. 2, 2023 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Class A Common Stock | 1659 | $0.00 | 3,198,463.0000 | 0 | 0.05% | 0.00% |
| April 21, 2023 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | G | Class A Common Stock | 627705 | $0.00 | 3,198,463.0000 | 0 | 16.41% | 0.00% |
| July 3, 2023 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Class A Common Stock | 1609 | $0.00 | 3,824,509.0000 | 0 | 0.04% | 0.00% |
| June 16, 2023 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Stock Option (Right to Buy) | 25224 | $0.00 | 89,292.0000 | 0 | 39.37% | 0.00% |
| June 16, 2023 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Class A Common Stock | 12612 | $0.00 | 3,823,069.0000 | 0 | 0.33% | 0.00% |
| May 2, 2023 | Merck & Co., Inc. | $MRK | Li Dean Y | Executive VP & President, MRL | A | Stock Option (Right to Buy) | 77455 | $0.00 | 77,455.0000 | 2,542,000,000 | 9999.99% | 0.00% |
| May 1, 2023 | Merck & Co., Inc. | $MRK | Li Dean Y | Executive VP & President, MRL | F | Common Stock | 524 | $115.47 | 20,471.4320 | 2,542,000,000 | 2.50% | 0.00% |
| May 1, 2023 | Merck & Co., Inc. | $MRK | Li Dean Y | Executive VP & President, MRL | M | Common Stock | 1062 | $115.47 | 20,995.4320 | 2,542,000,000 | 5.33% | 0.00% |
| May 1, 2023 | Merck & Co., Inc. | $MRK | Li Dean Y | Executive VP & President, MRL | M | Restricted Stock Unit | 1062 | $0.00 | 0.0000 | 2,542,000,000 | 100.00% | 0.00% |
| April 3, 2023 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Class A Common Stock | 1724 | $0.00 | 3,810,457.0000 | 0 | 0.05% | 0.00% |
| Jan. 23, 2023 | Merck & Co., Inc. | $MRK | Li Dean Y | Executive VP & President, MRL | A | Common Stock | 3275 | $109.88 | 19,933.4320 | 2,542,000,000 | 19.66% | 0.00% |
| Jan. 3, 2023 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Li Dean Y | Director | A | Class A Common Stock | 1573 | $0.00 | 3,808,733.0000 | 0 | 0.04% | 0.00% |